(Q36094448)

12 August 2017

1 reference

title

Hyperbilirubinemia in the setting of antiviral therapy (English)

1 reference

bilirubin metabolic disorder

12 August 2017

1 reference

2

Paul D Berk

1 reference

12 August 2017

Kevin M Korenblat

1

1 reference

PubMed ID

15822033

12 August 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

Clinical Gastroenterology and Hepatology

12 August 2017

1 reference

12 August 2017

3

1 reference

12 August 2017

303-310

1 reference

12 August 2017

4

1 reference

Studies of bilirubin kinetics in normal adults

12 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Unconjugated bilirubin exhibits spontaneous diffusion through model lipid bilayers and native hepatocyte membranes

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

ATP-dependent transport systems in the canalicular membrane of the hepatocyte

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Radixin deficiency causes conjugated hyperbilirubinemia with loss of Mrp2 from bile canalicular membranes

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Unconjugated hyperbilirubinemia. Physiologic evaluation and experimental approaches to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Investigation of the molecular basis of the genetic deficiency of UDP-glucuronosyltransferase in Crigler-Najjar syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Constitutional hepatic dysfunction (Gilbert's syndrome). A new definition based on kinetic studies with unconjugated radiobilirubin.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Molecular genetic basis of Gilbert's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Genetic defects in hepatocanalicular transport.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Infections of the liver in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Human immunodeficiency virus and the liver: lessons learned and still to be learned

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Hepatotoxicity of nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Mitochondrial toxicity of antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI)

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Toxicity of non-nucleoside analogue reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Indinavir: a review of its use in the management of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Symptomatic hyperbilirubinemia with indinavir/ritonavir-containing regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Mechanism of indinavir-induced hyperbilirubinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2805%2900083-2

7 January 2021

10.1016/S1542-3565(05)00083-2

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15822033